Table 2 Clinical study of antitumor drugs targeting cAMP–PKA pathway (from clinicaltrials.gov)
Identifier | Title | Cancer type | Locations |
|---|---|---|---|
NCT00004902 | Tocladesine in treating patients with recurrent or refractory multiple myeloma | Multiple myeloma and plasma cell tumor | Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois, United States |
NCT00021268 | Tocladesine in treating patients with recurrent or progressive metastatic colorectal cancer | Colorectal cancer | Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States |
NCT00004864 | Docetaxel and GEM 231 in treating patients with recurrent or refractory solid tumors | Unspecified adult solid tumor | Albert Einstein Comprehensive Cancer Center Bronx, New York, United States |
NCT00004863 | Paclitaxel and GEM 231 in treating patients with recurrent or refractory solid tumors | Unspecified adult solid tumor | Albert Einstein Comprehensive Cancer Center Bronx, New York, United States |